To study whether the alleviation of cholestasis can improve the therapeutical outcome of immune checkpoint blockade, we applied OCA treatment alone, anti-PD-1 treatment alone, and combination of OCA and anti-PD-1 to MC38-bearing BDL mice (Fig. 5A). Here, PDCD1 is linked to cholestasis.